Database

Startups

Main Industry
Biotechnology
Main Product/Service
Our pipeline is driven by our revolutionary research into immune response. Each product builds on our unique understanding of innate immunity and how this natural control can be used to destroy solid tumors or calm autoimmune inflammation. ASD141, our fir
Founded Year
2023
Unified Business No.
83000625
Status
Active
Number of Employees
0
Total Paid-in Capital
242,420,000 (NT$)
Location of Company
Taiwan , Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you. Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
About the Company
Ascendo Biotechnology is a clinical-stage pharmaceutical company founded in 2019. We leverage cutting-edge research in the field of dysregulated immune function to develop novel immunotherapy solutions for cancer and autoimmune diseases.



More ↓

Similar Companies

Great Novel Therapeutics Biotech & Medicals Corporation

GNTbm focuses on the R&D of oral new drugs in cancer immunotherapy, including tumor microenvironment regulators (TMRs), epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors.

HuniLife Biotechnology, Inc.

HuniLife is committed to developing first-in-class therapeutics for unmet medical need, indicating the innovation-pursuing nature of HuniLife. The products in development at HuniLife are acquired from renowned research institutes or companies through lice

Rock BioMedical, Inc.

Rock Bio’s Low-Sugar Universal Vaccine™ technology stems from pioneering glycoengineering research led by Professor Chi-Huey Wong and was recognized by IUPAC in 2023 as one of the Top 10 Emerging Technologies in Chemistry. This approach addresses viral im